Abstract
We read with great interest the recently published article titled “Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study” by Wen He et al, which concludes sirolimus can be used as a first-line antiepileptic drug in children with tuberous sclerosis (TSC) and can cause significant gain in development milestones [1]. However, we wish to add a few comments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
